If you’ve already registered, please click here to log in to the webcast.

Gene therapy has the potential to revolutionize medicine and improve the lives of millions of people. Adeno-associated virus (AAV) technology is an essential platform for gene therapies, as it has a low immunogenic profile and a diverse tropism for human tissues. However, a growing body of evidence suggests that the immune system can respond to AAV viral vectors used in gene therapies. This response is likely to be complex and multifactorial, just like the therapy itself.

Therefore, it is essential to understand how the host immune response impacts the efficacy, long-term durability, safety, immunogenicity and transgene expression potency in AAV gene therapy development.

In this webcast, industry experts will provide valuable insights into important aspects that must be discussed to move this exciting field forward.

• Important aspects of AAV efficacy and potency
• The significance, potential impact, and evaluation methods of the pre-existing humoral immune response to AAV vectors
• Current challenges and approaches for the innate immune response in relation to AAV